Adjuvant radiochemotherapy according to the EORTC/NCIC protocol has shown to improve the outcome of glioblastoma patients with a methylated MGMT-promoter status; however, overall survival remains limited [23]. The gene discussed is MGMT; the disease is glioblastoma.